Literature DB >> 30881038

Targeting off-target effects: endoplasmic reticulum stress and autophagy as effective strategies to enhance temozolomide treatment.

Yichun He1, Jing Su2, Beiwu Lan1, Yufei Gao1, Jingxia Zhao3.   

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive adult primary central nervous system tumor. Unfortunately, GBM is resistant to the classic chemotherapy drug, temozolomide (TMZ). As well as its classic DNA-targeting effects, the off-target effects of TMZ can have pro-survival or pro-death roles and regulate GBM chemoradiation sensitivity. Endoplasmic reticulum (ER) stress is one of the most common off-target effects. ER stress and its downstream induction of autophagy, apoptosis, and other events have important roles in regulating TMZ sensitivity. Autophagy is an evolutionarily conserved cellular homeostasis mechanism that is closely associated with ER stress-induced apoptosis. Under ER stress, autophagy cannot only remove misfolded/unfolded proteins and damaged organelles and degrade and inhibit apoptosis-related caspase activation to reduce cell damage, but may also promote apoptosis dependent on ER stress intensity. Although some protein interactions between autophagy and apoptosis and common upstream signaling pathways have been found, the underlying regulatory mechanisms are still not fully understood. This review summarizes the possible mechanisms underlying the current known off-target roles of ER stress and downstream autophagy in the regulation of cell fate and evaluates their role in TMZ treatment and their potential as therapeutic targets.

Entities:  

Keywords:  apoptosis; autophagy; chemotherapy resistance; endoplasmic reticulum stress; glioma; temozolomide

Year:  2019        PMID: 30881038      PMCID: PMC6413742          DOI: 10.2147/OTT.S194770

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


Introduction

Glioblastoma multiforme (GBM) is the most common and aggressive adult primary central nervous system tumor, with a 2-year survival rate of only 3%–5%.1 Currently, the standard treatment for GBM is a multimodal comprehensive approach that includes surgery, radiotherapy, and chemotherapy. Because complete surgical resection cannot be performed, and because of its multichemotherapy resistance, including the classic chemotherapeutic temozolomide (TMZ), recurrence is almost unavoidable, resulting in a very short median survival period of 12–15 months. To improve prognosis, research into the molecular mechanisms involved in resistance is imperative to increasing chemosensitivity. TMZ, an oral alkylated chemotherapeutic drug, is a first-line drug for clinical glioma chemotherapy and can efficiently pass through the blood–brain barrier to reach the lesion. However, over time, GBM develops resistance to TMZ-induced damage, which is associated with several mechanisms such as DNA repair pathways (O6- methylguanine DNA methyltransferase [MGMT], DNA mismatch repair, base excision repair system), epidermal growth factor receptor (EGFR) and MDM2 expression, p53 mutation, and PTEN expression. In addition, changes in micro-RNA expression profiles are also associated with resistance development. These mechanisms are centered on DNA repair and mutation of endogenous tumor suppressor genes. However, in addition to the classic targeting of DNA damage, TMZ induces some off-target effects, which may promote survival or death, resulting in regulation of GBM chemoradiation sensitivity. Among the off-target effects, endoplasmic reticulum (ER) stress is the most common. ER stress and its downstream signaling, such as autophagy and apoptosis, play an important role in regulating TMZ sensitivity. The ER is the intracellular organelle responsible for the synthesis of proteins and lipids. It can be disrupted by a variety of physiological or pathological stimuli (eg, withdrawal of nutrients, energy deprivation, hypoxia, oxidative stress, chemotherapeutic drugs) that can induce ER stress, leading to a decrease in ER protein folding ability and resulting in accumulation of misfolded or unfolded proteins, thereby activating the ER unfolded protein response (UPR). The UPR regulates autophagy and other degradation pathways that degrade misfolded proteins to restore homeostasis by limiting the rate of global protein synthesis, which finally determines cell fate. Autophagy, an important downstream target of ER stress, has been found to play a pro-survival or pro-apoptotic role at the cellular or organ level in response to different stresses.2 The exact mechanism by which autophagy performs two seemingly contradictory roles is still unclear. Current research shows that there is a complex interplay between autophagy and apoptosis. Therefore, during GBM chemotherapy, autophagy may be an important event resulting from off-target effects, leading to a change in TMZ sensitivity (Figure 1).3,4
Figure 1

Schematic representation of the functional relationship between unfolded protein response, autophagy, apoptosis, and glioma cell fate under TMZ treatment.

Notes: Under TMZ treatment, ER stress (unfolded protein response), autophagy, and apoptosis occur in glioma cells. Complex interactions between these pathways determine the fate of glioma cells. The UPR regulates autophagy through the PERK, XBP1, and other pathways, and autophagy can degrade misfolded protein aggregates or damaged organelles through a lysosome-associated degradation system. Meanwhile, upon ER stress stimulation, the UPR can facilitate apoptosis via CHOP, JNK, ATF6, and other pathways, or inhibit apoptosis through global translational control, and by regulating folding capacity and misfolded protein degradation through a proteasome-associated degradation system. iDISC formation and XIAP degradation are critical in the process of autophagy upregulation of apoptosis. However, autophagy can also inhibit apoptosis through nutrient recycling and elimination of damaged organelles.

Abbreviations: ER, endoplasmic reticulum; TMZ, temozolomide; UPR, unfolded protein response.

Thus, studies of the off-target effects of ER stress will contribute to develop new therapeutic strategies that sensitize chemoresistant glioma and/or prevent glioma resistance.

ER stress in GBM

ER stress can be observed in a variety of solid tumor samples (such as glioma), and studies have shown that it is closely related to the regulation of tumor chemosensitivity. The expression of the ER stress marker, 78 kDa glucose-regulated protein (GRP78), is lower in normal brain tissue than in other normal tissues, but it is most significantly increased in glioblastoma compared with other tumors.5 Furthermore, GRP78 expression significantly increases with the pathological grade level in gliomas.6 Several studies in glioma and other cancer cell line models have demonstrated that ER stress-associated proteins, such as GRP78/Bip,6–9 ATF4,10 ATF6,11 and P4HB,12,13 have pro-survival roles and function as resistance-related factors. These evidences indicate that ER stress and TMZ sensitivity of gliomas are closely related.

ER stress and UPR

Under ER stress, cells can activate a series of adaptive responses, such as the UPR. The UPR cannot only deal with stress by reducing new protein synthesis and increasing protein folding capacity, but can also reduce protein toxicity by reducing misfolded/unfolded protein accumulation through ER-associated protein degradation or autophagy. However, when stress persists or is too severe, the UPR initiates the apoptotic process to eliminate damaged cells. This indicates that the UPR determines cell survival and death depending on the stress intensity and duration. The UPR consists of three classical pathways, PERK–eIF2α–ATF4, IRE1α–XBP1, and ATF6. PERK, IRE1, and ATF6 are three transmembrane proteins that can form complexes with the molecular chaperone, GRP78, and remain inactive under physiological conditions. When ER stress occurs, unfolded proteins accumulate in the ER and GRP78/BiP is released from the complex, leading to PERK, IRE1, and ATF6 activation. PERK is a major protein that, under ER stress, reduces mRNA translation, inhibits global protein synthesis, and preferentially induces ATF4 expression by phosphorylating eIF2α.14 ATF4 is the core factor in the integration of the stress response, which can transcriptionally regulate autophagy, apoptosis, antioxidation, and other related proteins with its wide transcriptional capacity. ATF4 induces autophagy through transcriptional regulation of autophagy-related genes (eg, ATG7, ATG5, LC3B)15 and activates apoptosis by cooperating with upregulated CHOP and promoting XIAP degradation.16 CHOP initiates apoptosis by activating BIM and DR5 and inhibiting the antiapoptotic protein, BCL-2.17–19 DR5 is a death receptor that can be transcriptionally upregulated by CHOP and induces apoptosis by activating caspase-8.20 In addition, CHOP can induce apoptosis through the regulation of IP3R, which leads to changes in calcium homeostasis.21 Currently, PERK is the most studied branch of the UPR in the field of autophagy and apoptosis regulation by ER stress. When the UPR is activated, the cytoplasmic region of IRE1α oligomerizes and autophosphorylates and is activated by forming a complex with tumor necrosis factor receptor-associated factor-2 (TRAF2) and apoptosis signal-regulating kinase-1 (ASK-1), which in turn actives Jun-N-terminal kinase (JNK) and induces autophagy or apoptosis.22 Moreover, IRE1α can activate the apoptotic process by its RNase activity through the cleavage of miRNAs that inhibit caspase-2, such as miR-17, miR-34a, miR-96, and miR-125b.23 IRE1α can also induce autophagy by regulating the expression of Beclin-1 via XBP1.24 ATF6 is a transcription factor activated under ER stress, whereupon it translocates to the Golgi and is cleaved by S1P and S2P to its short form, which translocates to the nucleus and binds to the ATF/CRE element or the ERSE element to initiate target gene transcription (eg, GRP78, CHOP, XBP1) and regulate autophagy and apoptosis through XBP1 and CHOP.25

ER stress: a double-edged sword in TMZ sensitivity adjustment

The protective roles of ER stress

ER stress plays an important role in the resistance of GBM to TMZ toxicity by enhancing the ability of the molecular chaperones’ protein folding capacity and upregulating the ER-associated protein degradation pathway, autophagy, and other cellular adaptive responses. Currently, studies on the link between ER stress and TMZ chemoresistance have primarily focused on cellular models and on multiple glioma cell models. However, the exact mechanism has not yet been clarified. These studies suggest that GRP78 is crucial for the changes in glioma chemosensitivity.26 In GBM cell lines, knockdown of GRP78 by siRNA induced cell death by inducing CHOP expression and caspase-7 activation, whereas overexpression of GRP78 significantly increased the resistance of GBM cells to chemotherapeutic agents such as TMZ.9 Epigallocatechin 3-gallate (EGCG) is a green tea extract that inhibits GRP78 by targeting the ATP-binding domains and has been demonstrated to enhance GBM sensitivity to TMZ in vitro. Furthermore, using two pairs of TMZ-sensitive/resistant cell lines (D54-S and D54-R; U87-S and U87-R), Sun et al discovered that the ER stress-induced protein, prolyl 4-hydroxylase subunit beta (P4HB), has an important role in glioma TMZ resistance. P4HB is an ER stress-inducible multifunctional protein with disulfide isomerase activity and is overexpressed in TMZ-resistant and recurrent GBM. P4HB overexpression or siRNA knockdown in GBM cell lines resulted in resistance or sensitivity to TMZ.12 In addition, it has been shown that miR-210 is involved in the regulation of P4HB expression and confers GBM cell resistance to TMZ.13 Thus far, there is little evidence linking ER stress molecules with TMZ-resistance; most studies have focused on the cellular adaptive response mediated by ER stress, such as autophagy (described in detail below). By analyzing cell models, xenograft tumor models, human GBM pathology samples, and databases, Epple et al found that the UPR may generate resistance via regulation of cell metabolism.27 Moreover, it has been demonstrated at the cellular level that the ER stress factor, ATF4, can regulate oxidative metabolism through xCT (SLC7a11) and increase the resistance of glioma cells to TMZ.10 Thus, under mild ER stress, the activated UPR can maintain cellular homeostasis via activating molecular chaperones, inhibiting global protein synthesis, increasing the degradation of misfolded or unfolded proteins, changing the oxidative metabolism, and then inhibiting cell death, resulting in reduced sensitivity of GBM to chemotherapy.

ER stress acts as a pro-death mechanism

Under mild ER stress, a variety of cytoprotective effects can lead to glioma cell resistance to TMZ. However, under persistent and severe ER stress, cell homeostasis cannot be restored, resulting in the activation of various pathways. For instance, knockout of the ER stress-related factor mentioned above will transform protective ER stress into a fatal stress response. Hence, increasing the ER stress level has become a viable strategy for improved TMZ sensitivity. For example, sphingosine kinase inhibitors (SKIs) can increase TMZ toxicity through increasing ER stress, while the ER stress inhibitor 4-PBA reverses this sensitization effect.28 Fluoxetine, an antitumor-associated depression drug, works synergistically with TMZ through a CHOP-dependent apoptotic pathway mediated by ER stress. The new ER stress inducer, JLK1486, the systemic cancer chemotherapeutic drug, perillyl alcohol, and the novel trinorguaiane-type sesquiterpene, Radicol, can increase TMZ sensitization through CHOP by inducing lethal ER stress.29–31 Perillyl alcohol and TMZ have been conjugated to synthesize a new compound, NEO212, which shows stronger antiglioma properties, probably because of the enhanced apoptotic pathway of lethal ER stress.32 However, Xipell et al have found that ER stress-inducing agents can also increase the sensitivity of glioma cells to TMZ by downregulating MGMT, MPG, and Rad51.33 In conclusion, when ER stress is too severe, the UPR cannot restore homeostasis, and thus induces cell apoptosis through ATF4, CHOP, and other factors. Hence, increased ER stress may be an efficient target to enhance TMZ sensitivity. However, the specificity of its targets remains to be resolved.

ER stress-induced autophagy: the two faces of TMZ sensitivity regulation

At present, a variety of antitumor treatment methods (such as those that increase ER stress) cause autophagy in tumor cells. Autophagy is an important downstream ER stress event that has a double-edged sword role in ER stress largely through the regulation of apoptosis. Under ER stress, apoptosis occurs mainly through the mitochondrial pathways (endogenous) and death receptor pathways (exogenous). Numerous studies have shown that autophagy has a role in inhibiting or promoting apoptosis by participating in the critical steps of these two apoptosis pathways and in the regulation of crucial proteins.

Autophagy as a protective mechanism

Thus far, studies have shown that autophagy mainly acts as a pro-survival mechanism in the treatment of glioma with TMZ. Inhibition of autophagy can significantly increase TMZ-induced apoptosis at the clinical treatment concentration (#100 µM), indicating that inhibition of autophagy is an effective strategy for improving the therapeutic effect of TMZ.34,35 Knockout of critical autophagy genes (eg, ATG5, ATG7, BECN1) or autophagy blockers (eg, chloroquine and its derivatives) can increase ER stress-related apoptosis, leading to increased CHOP expression and caspase-3 and PARP cleavage.36,37 This evidence suggests that autophagy has an important role in degrading unfolded proteins, reducing protein load, and promoting cell survival. In addition, ER stress can induce mitochondrial autophagy, degrade damaged mitochondria, and protect cells from death.38 Autophagy can protect cells from apoptosis by clearing unfolded proteins, reducing protein load, and eliminating damaged organelles (mainly mitochondria), as well as reduce apoptosis by regulating the activity of caspase family proteins. Studies have shown that inhibiting autophagy by knockdown of BECN1 (which encodes Beclin1) and VPS34 obviously increased the activation of caspase-8, the release of cytochrome C, and the proportion of Annexin V-positive cells in apoptosis-deficient cell lines HCT116 (BAX-/-) and MCF-7 (CASP3-/-) treated with the exogenous apoptosis pathway-inducing drug, TRAIL, and the classic chemotherapy drug, cisplatin. This effect was counteracted by caspase-8 inhibitors and caspase-8-targeting RNAi.39 These findings suggest that inhibiting autophagy mediated by ER stress and induced by the inhibition of the death receptor and chemotherapeutic drugs increases caspase-8 activation in apoptotic cell lines. Similarly, Amir et al have demonstrated that autophagy occurs during hepatocyte apoptosis induced by D-galactosamine (GalN) and lipopolysaccharide (LPS) in mice, and inhibiting autophagy by hepatic tissue-specific inhibition of ATG7 increased hepatocellular caspase-8 activity and apoptosis.40 Zhang et al have demonstrated that autophagy protected U87MG glioma cells from H2O2-induced oxidative stress by degrading caspase-8.41 Taken together, these findings suggest that autophagy contributes to avoidance of apoptosis by blocking caspase-8 activation. It has been demonstrated that blocking autophagic flux can increase TMZ sensitization,36–38,42 and combination TMZ adjuvant therapy has entered Phase I/II clinical trials.43 In addition, several experiments have demonstrated that ataxia telangiectasia mutated (ATM) kinase inhibitors and plant extracts (eg, resveratrol) inhibited autophagy in both cellular models and mouse xenograft tumor models, and markedly enhanced TMZ cytotoxicity, reduced tumor volume, and increased mouse lifespan.44–48 However, these experiments did not involve analysis of caspase family proteins. Whether autophagy is involved in the regulation of caspase activity under the action of TMZ requires further study. In conclusion, autophagy has a protective role in ER stress by clearing misfolded proteins and damaged organelles (mainly mitochondria) and by inhibiting caspase-8 activity.

Autophagy as a pro-death mechanism

Although autophagy under ER stress can degrade misfolded/unfolded proteins to maintain cellular homeostasis and inhibit cell death, it can also participate in ER stress-induced apoptosis.49 Autophagy-associated cell death is currently thought to result from complete degradation of cellular components caused by excessive autophagy. In T98G glioma cells, silencing of the critical autophagy genes BECN1 and ATG7 by siRNA partially decreased the cytotoxicity of TMZ.50 In addition, drugs that promote autophagy-mediated apoptosis such as Δ9-tetrahydrocannabinol51 and oncolytic adenovirus CRAd–Surivin–pk7,52 in combination with TMZ, significantly reduced the volume of xenograft tumors. Furthermore, dasatinib,53 rapamycin,50 the dual class IA inhibitor of PI3K/mTOR, PI-103,54 pan BCL-2 inhibitors,55 and VPA56 improved the TMZ effect through autophagy in different GBM cell lines. Studies on ER stress have indicated that the autophagosomal membrane serves as a platform for intracellular death-inducing signaling complex (iDISC), which mediates caspase-8 activation and apoptosis. In 1998, Martin et al found that forced membrane localization and self-association of caspase-8 promoted apoptosis.57 Furthermore, it has been demonstrated that caspase-8 can be recruited to the ATG12ATG5 complex by FADD and that the autophagic machinery has an important role in caspase-8 activation.58–60 Moreover, Young et al found that the caspase-8FADD complex colocalized with ATG5 in ATG16- and LC3-positive structures upon treatment with SKI-I (a pan-sphingosine kinase inhibitor) and bortezomib (a proteasome inhibitor), indicating that the autophagosomal membrane serves as a platform for this complex and demonstrated that the recruitment of caspase-8 to this complex depends on p62/SQSTM1.61 Inhibition of the early stage of autophagy through knockdown of ATG5 or ATG3 significantly reduced caspase-8 activation and apoptosis, whereas inhibiting late-stage autophagic flux with bafilomycin A1 increased caspase-dependent cell death.61 Furthermore, using HAMLET treatment, Zhang et al demonstrated that p62/SQSTM1 is involved in the regulation of apoptosis by regulating caspase-8 activation in U87MG glioma cells and that the p62/SQSTM1 UBA domain is required for it to activate caspase-8.62 And another study showed that E3 ubiquitin ligase TRIM13 could regulate caspase-8 ubiquitination and translocation to autophagosomal membranes under ER stress.63 And in mitochondrial apoptotic pathway-deficient cell lines, ER stress inducers tunicamycin and thapsigargin promoted the formation of ATG5FADDcaspase-8 complexes and caspase-8 activation.39 Furthermore, Tang et al found that caspase-8 dimerization and activation based on iDISC formation occur on accumulated immature autophagosomal membranes and require the LC3 conjugation machinery.64 Inhibiting the initial stages of autophagy by knocking out ATG5 and ATG7 decreased caspase-8-dependent apoptosis.39,65 Conversely, increased induction of autophagy would make the cell sensitive to autophagy blockers such as chloroquine and bafilomycin A1 through p62/SQSTM1-dependent caspase-8 activation.66–68 However, autophagy could also play a cytoprotective role by degrading caspase-8 or blocking intrinsic or extrinsic apoptosis pathways, and inhibiting autophagy initiation by siRNA or inhibitors enhances the activation of caspase-8 and apoptosis.40,41,69 However, the factors that determine the completion of the autophagy process or that serve as a platform for caspase-8 activation and iDISC formation remain unknown. In addition to the regulation of apoptosis through the interaction with caspases, autophagy may promote apoptosis by degrading endogenous antiapoptotic factors. Inhibitors of apoptosis (IAPs) are an evolutionarily conserved protein family that inhibit apoptosis by inactivating caspases.70 Hou et al found that ATG1 and ATG7 mutations caused a decrease in DNA fragmentation, but did not affect nuclear condensation in degenerating mid-stage egg chambers, indicating that autophagy is partially involved in the regulation of cell death. During this stage, the effector caspase, DCP-1, and the IAP protein, Bruce, closely interact with autophagy.71 Subsequently, Nezis et al revealed that inhibiting autophagy by knocking out ATG1, ATG13, and type III PI3K (VPS34) blocks developmental apoptosis in the late-stage nurse cells of Drosophila melanogaster oogenesis. Furthermore, it has been shown that dBruce colocalized with the autophagy marker, ATG8-GFP, and accumulated in autophagy-mutated cells.72,73 Xu et al demonstrated that CHAL-24 induced the degradation of c-FLIP (L) and c-IAP via autophagy, thereby significantly enhancing the antitumor activity of TRAIL.74 Additionally, it has been reported that the PERK–eIF2α–ATF4 pathway of the UPR is involved in the degradation of the antiapoptotic protein, XIAP.16 Although the PERK axis is closely related to autophagy, whether autophagy is directly involved in the degradation of XIAP protein still lacks direct experimental evidence. Taken together, this evidence demonstrates that autophagy can promote apoptosis by autophagic degradation of certain types of IAPs. In summary, autophagy undertakes a cytoprotective role by eliminating misfolded/unfolded proteins and damaged organelles and inhibiting the activation of caspases under ER stress. It also serves as a platform for the activation of caspase-8 and degradation of IAPs, promoting ER stress-induced apoptotic death. However, the role of autophagy in the treatment of GBM with TMZ remains controversial, and the mechanism by which autophagy switches between a pro-survival and a pro-death role remains unclear. Combining the close relationship between ER stress and autophagy, it is likely that ER stress determines the role of autophagy in the regulation of cell survival and death. Hence, we propose the following model: in mild or moderate ER stress, the activated UPR maintains cellular homeostasis by inhibiting new protein synthesis and increasing protein folding capacity, in which autophagy has an important role by eliminating misfolded/unfolded proteins and inhibiting or degrading caspases. In severe ER stress, the UPR activates the apoptotic process by CHOP and other proteins, while autophagy serves as a platform for the activation of caspase-8 to promote apoptosis. This hypothetical model considers that autophagy specifically determines the fate of cells under ER stress, and that ER function is mainly mediated through the modulation of autophagy function (Figure 2).
Figure 2

Common upstream signaling pathways of autophagy and apoptosis under ER stress and the mechanisms of autophagy involved in determining cell fate under different intensities of ER stress.

Notes: Under ER stress, the unfolded protein response is activated, resulting in activation of PERK and phosphorylation of eIF2α. Selective induction of ATF4 occurs, which can promote the transcription of genes involved in autophagy, apoptosis, molecule chaperoning, ER-associated degradation, and metabolism. Moreover, ATF4 can also activate apoptosis via degradation of XIAP and cooperation with CHOP under prolonged ER stress. IRE1 activates XBP1, ASK1, and molecules downstream of JNK that promote autophagy and apoptosis. Through XBP1 and CHOP, ATF6 can indirectly regulate autophagy or apoptosis. Thus, the effects of ER stress-induced autophagy on cell survival have dual roles including pro-survival and pro-death. On one hand, autophagy can inhibit apoptosis through clearing misfolded/unfolded proteins and damaged organelles and inhibiting or degrading caspases, resulting in protecting cells from damages induced by ER stress. On the other hand, autophagy can serve as a platform for caspase-8 activation and degrade IAPs, which amplifies cell injury induced by ER stress.

Abbreviations: ER, endoplasmic reticulum; TMZ, temozolomide.

Conclusion and prospect

The resistance of GBM to TMZ treatment is the bottleneck in the clinical treatment of this disease. The off-target effects of ER stress have various and intricate outcomes on the sensitivity of GBM to chemotherapy (mainly TMZ). Undoubtedly, ER stress and autophagy are crucial regulators of TMZ sensitivity but may be more likely to function in a cell-specific manner. Finally, the survival and death of GBM cells theoretically depend on the dose and duration of TMZ treatment, the DNA repair capacity of cells, the rate of proliferation, and the critical proteins that activate DNA repair, such as ATM. However, it is unclear to how the mechanism of ER stress and autophagy transition between pro-survival and pro-apoptosis roles to ultimately determine cell fate. Under low doses and short-term TMZ treatment, ER stress and autophagy may have a cytoprotective role; however, it is unknown if they have a role in promoting cell death. If this hypothesis is validated, the dose and duration of TMZ treatment will become an important factor affecting prognosis after chemotherapy. The switch between the pro-survival and pro-death effects induced by ER stress and its downstream autophagy in different therapeutic environments requires further exploration. It is of great importance to develop more combinatorial solutions that will increase glioblastoma sensitivity to TMZ and reduce off-target effects.
  13 in total

1.  Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.

Authors:  Lianxin Li; Zhihao Yang; Yinfei Zheng; Zhigang Chen; Xiaoyu Yue; Erbao Bian; Bing Zhao
Journal:  BMC Neurol       Date:  2022-05-25       Impact factor: 2.903

Review 2.  Regulation of autophagy by canonical and non-canonical ER stress responses.

Authors:  Monika Bhardwaj; Nektaria Maria Leli; Constantinos Koumenis; Ravi K Amaravadi
Journal:  Semin Cancer Biol       Date:  2019-12-12       Impact factor: 15.707

Review 3.  The Multifaceted Role of CMA in Glioma: Enemy or Ally?

Authors:  Alessia Lo Dico; Cristina Martelli; Cecilia Diceglie; Luisa Ottobrini
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

4.  Four specific biomarkers associated with the progression of glioblastoma multiforme in older adults identified using weighted gene co-expression network analysis.

Authors:  Yushi Yang; Liangzhao Chu; Zhirui Zeng; Shu Xu; Hua Yang; Xuelin Zhang; Jun Jia; Niya Long; Yaxin Hu; Jian Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.

Authors:  Neha Singh; Alexandra Miner; Lauren Hennis; Sandeep Mittal
Journal:  Cancer Drug Resist       Date:  2021-03-19

6.  Aspirin Induced Glioma Apoptosis through Noxa Upregulation.

Authors:  Cheng-Yi Chang; Ping-Ho Pan; Jian-Ri Li; Yen-Chuan Ou; Jiaan-Der Wang; Su-Lan Liao; Wen-Ying Chen; Wen-Yi Wang; Chun-Jung Chen
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

7.  Endoplasmic Reticulum Stress Contributes to Indomethacin-Induced Glioma Apoptosis.

Authors:  Cheng-Yi Chang; Jian-Ri Li; Chih-Cheng Wu; Jiaan-Der Wang; Su-Lan Liao; Wen-Ying Chen; Wen-Yi Wang; Chun-Jung Chen
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

Review 8.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

9.  Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma.

Authors:  Zili Zhai; Jenny Mae Samson; Takeshi Yamauchi; Prasanna K Vaddi; Yuko Matsumoto; Charles A Dinarello; Dinoop Ravindran Menon; Mayumi Fujita
Journal:  Cancers (Basel)       Date:  2020-09-04       Impact factor: 6.639

10.  KDELR2 knockdown synergizes with temozolomide to induce glioma cell apoptosis through the CHOP and JNK/p38 pathways.

Authors:  Guofeng Zhang; Bin Wang; Shiqi Cheng; Hengyi Fan; Shaowen Liu; Bin Zhou; Weibin Liu; Rui Liang; Youjia Tang; Yan Zhang
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.